WilmerHale Guides $90M IPO For Kala Pharmaceuticals
Stock in Kala Pharmaceuticals Inc., a biopharmaceutical company working on therapeutic applications of its mucus-penetrating nanoparticle technology, debuted Thursday after the firm priced its $90 million initial public offering under guidance...To view the full article, register now.
Already a subscriber? Click here to view full article